Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.58 |
| ▸ | CDK7 | P50613 | 12/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.52 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL624999 | 0.91 | FLT3 (0.68) | FLT3CDK7KITNTRK3CDK2 | |
| SCHEMBL1336402 | 0.90 | NTRK1 (0.53) | FLT3CDK7KITNTRK1NTRK3 | |
| SCHEMBL1336312 | 0.89 | ULK1 (0.53) | FLT3CDK7KITNTRK1NTRK3 | |
| SCHEMBL1336528 | 0.89 | NTRK1 (0.52) | FLT3CDK7KITNTRK1NTRK3 | |
| SCHEMBL1336217 | 0.89 | FLT3 (0.49) | FLT3CDK7KITNTRK1NTRK3 | |
| SCHEMBL12127155 | 0.89 | FLT3 (0.51) | FLT3CDK7KITNTRK1NTRK3 | |
| SCHEMBL14641956 | 0.87 | FLT3 (0.47) | FLT3CDK7KITNTRK1NTRK3 | |
| SCHEMBL18030719 | 0.87 | FLT3 (0.45) | FLT3CDK7KITNTRK1NTRK3 | |
| SCHEMBL1335600 | 0.87 | NTRK1 (0.50) | FLT3CDK7KITNTRK1NTRK3 | |
| SCHEMBL1334911 | 0.86 | MEN1 (0.55) | FLT3NTRK1NTRK3NTRK2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373626-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-24 | — | — | EP | disclosed |
| US-8354399-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-15 | — | — | US | disclosed |
| US-8354399-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-15 | — | — | US | disclosed |
| US-20110281843-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-11-17 | — | — | US | disclosed |
| US-20110281843-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2373626-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010069966-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281843-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | FLT3 241/4885CDK7 146/4885KIT 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.